These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers. Kozer N; Kelly MP; Orchard S; Burgess AW; Scott AM; Clayton AH Biochemistry; 2011 May; 50(18):3581-90. PubMed ID: 21495621 [TBL] [Abstract][Full Text] [Related]
3. The ErbB/HER family of protein-tyrosine kinases and cancer. Roskoski R Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963 [TBL] [Abstract][Full Text] [Related]
7. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. Tao RH; Maruyama IN J Cell Sci; 2008 Oct; 121(Pt 19):3207-17. PubMed ID: 18782861 [TBL] [Abstract][Full Text] [Related]
8. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners. Li Z; Mei Y; Liu X; Zhou M Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839 [TBL] [Abstract][Full Text] [Related]
9. EGFR kinase possesses a broad specificity for ErbB phosphorylation sites, and ligand increases catalytic-centre activity without affecting substrate binding affinity. Fan YX; Wong L; Johnson GR Biochem J; 2005 Dec; 392(Pt 3):417-23. PubMed ID: 16122376 [TBL] [Abstract][Full Text] [Related]
10. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. Yu X; Sharma KD; Takahashi T; Iwamoto R; Mekada E Mol Biol Cell; 2002 Jul; 13(7):2547-57. PubMed ID: 12134089 [TBL] [Abstract][Full Text] [Related]
11. Active and inactive conformations of the epidermal growth factor receptor. Ferguson KM Biochem Soc Trans; 2004 Nov; 32(Pt 5):742-5. PubMed ID: 15494003 [TBL] [Abstract][Full Text] [Related]
12. Comparative experimental/theoretical studies on the EGFR dimerization under the effect of EGF/EGF analogues binding: Highlighting the importance of EGF/EGFR interactions at site III interface. Mehrabi M; Mahdiuni H; Rasouli H; Mansouri K; Shahlaei M; Khodarahmi R Int J Biol Macromol; 2018 Aug; 115():401-417. PubMed ID: 29665393 [TBL] [Abstract][Full Text] [Related]
13. Role of N-glycosylation in EGFR ectodomain ligand binding. Azimzadeh Irani M; Kannan S; Verma C Proteins; 2017 Aug; 85(8):1529-1549. PubMed ID: 28486782 [TBL] [Abstract][Full Text] [Related]
14. Quantitation of the effect of ErbB2 on epidermal growth factor receptor binding and dimerization. Li Y; Macdonald-Obermann J; Westfall C; Piwnica-Worms D; Pike LJ J Biol Chem; 2012 Sep; 287(37):31116-25. PubMed ID: 22822073 [TBL] [Abstract][Full Text] [Related]
15. Evidence for extended YFP-EGFR dimers in the absence of ligand on the surface of living cells. Kozer N; Henderson C; Jackson JT; Nice EC; Burgess AW; Clayton AH Phys Biol; 2011 Dec; 8(6):066002. PubMed ID: 21946082 [TBL] [Abstract][Full Text] [Related]
16. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth. Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620 [TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020 [TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor mutant with wild-type affinity for both ErbB1 and ErbB3. Wingens M; Jacobs-Oomen S; van der Woning SP; Stortelers C; van Zoelen EJ Biochemistry; 2006 Apr; 45(14):4703-10. PubMed ID: 16584205 [TBL] [Abstract][Full Text] [Related]
20. The ErbB/HER receptor protein-tyrosine kinases and cancer. Roskoski R Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]